Ovarian Cancer Clinical Roundup

News Articles

(Medscape Medical News) Oct 28, 2020 - New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC). However, trials investigating retreatment are underway, so this recommendation may change.
(Markets Insider) Oct 27, 2020 - Sumitomo Dainippon Pharma Oncology, Inc. today announced the first patient has been dosed in the Phase 2 expansion portion of the study evaluating DSP-7888, an investigational immunotherapeutic cancer vaccine that targets Wilms Tumor 1 (WT1), in combination with checkpoint inhibitor pembrolizumab, in...
(Foundation Medicine) Oct 27, 2020 - Foundation Medicine, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved FoundationOne®Liquid CDx for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies. The new indications are...
(Purdue University) Oct 22, 2020 - Scientists estimate that nearly 60% of all cancer patients do not respond effectively to chemotherapy treatments. Even worse – many of those same patients experience toxic and sometimes deadly side effects.
View all ovarian cancer news

Journal Scans


Case Studies


Dr. Slomovitz, Professor of Obstetrics and Gynecology, Florida International University, Gynecologic Oncologist, Broward Health, and Dr. Jordan, Obstetrician/Gynecologist, Broward Health, discuss high-grade serous ovarian cancer recurrence

Clinical Briefs

PARP inhibition continues to steal the spotlight in advanced ovarian cancer, even in the absence of pivotal trial data. Findings presented at the European Society of Medical Oncology (ESMO) Virtual Congress 2020 showed a significant benefit for PARP inhibition earlier in the cancer pathway, offering hope for more long-term survivors, while other treatment paradigms such as immunotherapy failed again to make headway against the disease.

Featured Ovarian Cancer Tweets

Mario M. Leitao, Jr., MD, FACOG, FACS
leitaomd - Oct 27  Great question that we can’t answer. Follow-up then is after 6 in these great responders what to do after surgery? https://t.co/A4iKKWJ9Yv

Mario M. Leitao, Jr., MD, FACOG, FACS
leitaomd - Oct 27  @BatistaTP @praveen_kmio @sbco_oficial @TeamOvary_MSK Good points. And if all high grade serous cancers will reciev… https://t.co/liEpzuROYB

Elizabeth M. Swisher, MD
SwisherLiz - Oct 25  @jeffreyswisher @karaswisher Gynecologic oncologist at UW in Seattle, about 70% research. Small world.

Don S. Dizon, MD, FACP, FASCO
drdonsdizon - Oct 24  FINALLY!!! #GOG209 published and sets Carbo/Taxol as standard of care in #endometrialcancer. #gyncsm https://t.co/fHYxbRsj9M